← Eichor
Study identifier: NCT06935370 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

Condition: Heart Failure  ·  Sponsor: Boehringer Ingelheim

PhasePhase 3
Planned participants4200
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF) of less than 40%. People can join the study if they have been diagnosed with chronic HF at least 3 months before they start on the study. The purpose of this study is to find out whether a medicine called vicadrostat, in combination with another medicine called empagliflozin, helps people with chronic heart failure. In this study, participants are put into 2 groups randomly. Participants have an equal chance of being in either group. One group takes vicadrostat/empagliflozin tablets, and the other group takes placebo/empagliflozin tablets. Placebo tablets look like vicadrostat tablets but do not contain any medicine. Participants take the study medicines as tablets once a day for between about 6 months and about 3.5 years. During this time, they can continue their regular treatment for heart failure. Participants can stay in the study as long as they benefit from treatment and can tolerate it, for a maximum of about 3.5 years. During this time, they visit the study site regularly. The exact number of visits is different for each participant, depending on how long they stay in the study. The study staff may also contact the participants by phone for some visits. Participants also regularly answer questions about their well-being. The doctors document when participants experience worsening of their heart failure symptoms, go to hospital due to heart failur…

This description comes directly from the study's public registry record.

Talk to the study team

Boehringer Ingelheim  ·  1-800-243-0127  ·  clintriage.rdg@boehringer-ingelheim.com

Always discuss trial participation with your own doctor first.

Locations (632)

Drug Research and Analysis CorporationMontgomery, Alabama, United StatesNot Yet Recruiting
Cure Clinical ResearchBeverly Hills, California, United StatesSuspended
Valley Clinical Trials, Inc.Covina, California, United StatesRecruiting
North Coast CardiologyEncinitas, California, United StatesNot Yet Recruiting
Orange County Research CenterLake Forest, California, United StatesNot Yet Recruiting
Merced Vein and Vascular CenterMerced, California, United StatesRecruiting
Radin Cardiovascular Medical GroupNewport Beach, California, United StatesNot Yet Recruiting
Amicis Research Center - NordhoffNorthridge, California, United StatesTerminated
University of California San DiegoSan Diego, California, United StatesNot Yet Recruiting
Paradigm Clinical Research - San DiegoSan Diego, California, United StatesNot Yet Recruiting
Amicis Research CorporateSanta Clarita, California, United StatesTerminated
Care Access ResearchThousand Oaks, California, United StatesNot Yet Recruiting

+ 620 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06935370